Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia

European Journal of Cancer

Volumn 39, Issue 14, 2003, Pages 2099-2102

  Yorke, R ^a   Younes, A ^b   Chirala, M ^c   Younes, M ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Barrett's oesophagus; Cancer; Immunohistochemistry; Metaplasia; RANK

Indexed keywords

FORMALDEHYDE; OSTEOCLAST DIFFERENTIATION FACTOR; PARAFFIN; CELL RECEPTOR; GLYCOPROTEIN; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL; CANCER GRADING; CANCER GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DYSPLASIA; EMBEDDING; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MALIGNANT NEOPLASTIC DISEASE; METAPLASIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STAINING; TISSUE SECTION; DISEASE COURSE; ESOPHAGUS TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; MIDDLE AGED; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0142026185     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00434-9     Document Type: Article

References (31)

1. Anderson D.M., Maraskovsky E., Billingsley W.L.et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:1997;175-179.
2. Wong B.R., Josien R., Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc.ite Biol. 65:1999;715-724.
3. Darnay B.G., Haridas V., Ni J., Moore P.A., Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J. Biol. Chem. 273:1998;20551-20555.
4. Galibert L., Tometsko M.E., Anderson D.M., Cosman D., Dougall W.C. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J. Biol. Chem. 273:1998;34120-34127.
5. Wong B.R., Josien R., Lee S.Y., Vologodskaia M., Steinman R.M., Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 273:1998;28355-28359.
6. Arron J.R., Choi Y. Bone versus immune system. Nature. 408:2000;535-536.
7. Dougall W.C., Glaccum M., Charrier K.et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13:1999;2412-2424.
8. Wong B.R., Josien R., Lee S.Y.et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186:1997;2075-2080.
9. Josien R., Wong B.R., Li H.L., Steinman R.M., Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162:1999;2562-2568.
10. Fata J.E., Kong Y.Y., Li J.et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 103:2000;41-50.
11. Kim Y.M., Lee Y.M., Kim H.S.et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J. Biol. Chem. 277:2002;6799-6805.
12. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am. J. Pathol. 159:2001;387-397.
13. Grundker C., Schulz K., Gunthert A.R., Emons G. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J. Clin. Endocrinol. Metab. 85:2000;3815-3820.
14. Finke J.H., Rayman P., George R.et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma. role of nuclear factor-kappaB suppression Clin. Cancer Res. 7:2001;940. s-946s.
15. Huang S., DeGuzman A., Bucana C.D., Fidler I.J. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin. Cancer Res. 6:2000;2573-2581.
16. Lim J.W., Kim H., Kim K.H. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab. Invest. 81:2001;349-360.
17. Muenchen H.J., Lin D.L., Walsh M.A., Keller E.T., Pienta K.J. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super- repressor" Clin. Cancer Res. 6:2000;1969-1977.
18. Fiumara P., Snell V., Li Y.et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 98:2001;2784-2790.
19. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum. Pathol. 25:1994;982-993.
20. Younes M., Henson D.E., Ertan A., Miller C.C. Incidence and survival trends of esophageal carcinoma in the United States. racial and gender differences by histological type Scand. J. Gastroenterol. 37:2002;1359-1365.
21. Li J.J., Westergaard C., Ghosh P., Colburn N.H. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res. 57:1997;3569-3576.
22. He Z., Xin B., Yang X., Chan C., Cao L. Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts. Cancer Res. 60:2000;1845-1848.
23. Hsu T.C., Young M.R., Cmarik J., Colburn N.H. Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic. Biol. Med. 28:2000;1338-1348.
24. Miros M., Kerlin P., Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus [see comments]. Gut. 32:1991;1441-1446.
25. Reid B.J., Weinstein W.M., Lewin K.J.et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 94:1988;81-90.
26. Andela V.B., Schwarz E.M., Puzas J.E., O'Keefe R.J., Rosier R.N. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res. 60:2000;6557-6562.
27. Berman K.S., Verma U.N., Harburg G., Minna J.D., Cobb M.H., Gaynor R.B. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin. Cancer Res. 8:2002;354-360.
28. Kawai H., Yamada Y., Tatsuka M., Niwa O., Yamamoto K., Suzuki F. Down-regulation of nuclear factor kappaB is required for p53-dependent apoptosis in X-ray-irradiated mouse lymphoma cells and thymocytes. Cancer Res. 59:1999;6038-6041.
29. Otsuka G., Nagaya T., Saito K., Mizuno M., Yoshida J., Seo H. Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Cancer Res. 59:1999;4446-4452.
30. Shinohara T., Miki T., Nishimura N.et al. Nuclear factor-kappaB- dependent expression of metastasis suppressor KAI1/CD82 gene in lung cancer cell lines expressing mutant p53. Cancer Res. 61:2001;673-678.
31. van Hogerlinden M., Rozell B.L., Ahrlund-Richter L., Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res. 59:1999;3203-3299.